NSE: BIOCON | BSE: 532523

Slowing Down Stock

Download real time

316.55 10.25 (3.35%)

3.3M NSE+BSE Volume

NSE 11 Apr, 2025 3:31 PM (IST)

38,005

Market Cap

Market Leader

1.2

Beta 1Year

Very High Volatility

US FDA Approval

Biocon receives USFDA approval for Jobevne, used in cancer treatment, with a market size of ~$2 bn See details

Biocon Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Biocon Ltd. from all sources in a single place.

Is Biocon Ltd. worth buying?

714 Votes:

Buy 75.07%

Sell 16.39%

Hold 8.54%

RESEARCH REPORTS

Buy SEE REPORTS >

Buy SEE REPORTS >